afatinib
Showing 26 - 50 of 96
Carcinoma, Squamous Cell of Head and Neck Trial in France (Afatinib)
Completed
- Carcinoma, Squamous Cell of Head and Neck
- Afatinib
-
Angers, France
- +10 more
Feb 1, 2022
NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)
Recruiting
- NSCLC Stage IV
- therapeutic thoracic surgery
- Afatinib
-
Taipei, Taiwan
- +1 more
Mar 8, 2022
Gallbladder Carcinoma Trial in Shanghai (gemcitabine and oxaliplatin., Afatinib)
Recruiting
- Gallbladder Carcinoma
- gemcitabine and oxaliplatin.
- Afatinib
-
Shanghai, Shanghai, China
- +1 more
Dec 21, 2022
Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)
Recruiting
- Rare Tumor
- Refractory Tumor
- Gefitinib
- +11 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Feb 16, 2022
HER2/Neu+ Uterine Serous Carcinoma Trial in Tucson, New Haven, Boston (Afatinib)
Recruiting
- HER2/Neu+ Uterine Serous Carcinoma
- Afatinib
-
Tucson, Arizona
- +2 more
Feb 2, 2022
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
Afatinib Osimertinib Sequencing NIS
Completed
- Carcinoma, Non-Small-Cell Lung
- Afatinib
- Osimertinib
-
Vienna, AustriaOtto-Wagner Hospital
Dec 23, 2020
Squamous Cell Carcinoma of the Head and Neck Trial in Boston, New York (Afatinib, Docetaxel, Radiation Therapy)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Afatinib
- +2 more
-
Boston, Massachusetts
- +2 more
Jan 25, 2021
Head and Neck Squamous Cell Carcinoma Trial in France (AFATINIB, Placebo of AFATINIB)
Completed
- Head and Neck Squamous Cell Carcinoma
- AFATINIB
- Placebo of AFATINIB
-
Angers, France
- +25 more
May 28, 2021
Epidermal Growth Factor Receptor Mutations in Advanced EGFR
Completed
- Non Small Cell Lung Cancer
- +2 more
- Afatinib
- (no location specified)
Dec 22, 2020
NSCLC Trial in Worldwide (Afatinib, pembrolizumab)
Completed
- Carcinoma, Non-Small-Cell Lung
- Afatinib
- pembrolizumab
-
Lexington, Kentucky
- +12 more
Feb 5, 2021
Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon Trial in United States (afatinib,
Completed
- Non-small Cell Lung Carcinoma
- +3 more
- afatinib
- +2 more
-
Denver, Colorado
- +7 more
Aug 17, 2022
Lung Cancer, Breast Cancer, Brain Cancer Trial in United Kingdom (Afatinib, 2 Gy targeted radiotherapy, 4 Gy targeted
Unknown status
- Lung Cancer
- +4 more
- Afatinib
- +2 more
-
Cambridge, England, United Kingdom
- +5 more
Jan 12, 2021
Lung Cancer Trial in Boston (drug, radiation, procedure)
Unknown status
- Lung Cancer
- Afatinib
- +4 more
-
Boston, Massachusetts
- +1 more
Jul 1, 2020
Neuroectodermal Tumors, Rhabdomyosarcoma Trial in Worldwide (afatinib)
Completed
- Neuroectodermal Tumors
- Rhabdomyosarcoma
- afatinib
-
Boston, Massachusetts
- +27 more
Mar 3, 2021
Non Small Cell Lung Cancer Trial in Palo Alto, Boston, New York (Afatinib)
Unknown status
- Non Small Cell Lung Cancer
- Afatinib
-
Palo Alto, California
- +3 more
Jul 1, 2020
NSCLC Trial in Worldwide (afatinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- afatinib
-
Randwick, New South Wales, Australia
- +117 more
Aug 23, 2022
Squamous Cell Carcinoma Trial in Singapore (Afatinib)
Not yet recruiting
- Squamous Cell Carcinoma
- Afatinib
-
Singapore, SingaporeNational University Hospital
Aug 26, 2020
HER2-positive Breast Cancer, Brain Metastases Trial in China (Afatinib, T-DM1)
Recruiting
- HER2-positive Breast Cancer
- Brain Metastases
- Afatinib
- T-DM1
-
Beijing, Beijing, China
- +3 more
May 9, 2020
Bevacizumab Plus EGFR-TKIs in Chinese EGFR-mutant
Recruiting
- NSCLC
- Bevacizumab
- +6 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Oct 17, 2020
Advanced NSCLC With EGFR-mutations
Completed
- Carcinoma, Non-Small-Cell Lung
- Afatinib
-
Multiple Locations, Germany(unnamed)
Dec 19, 2019
NSCLC, ErbB Receptors Trial in United States (Afatinib)
Completed
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Afatinib
-
Scottsdale, Arizona
- +9 more
Mar 16, 2020
Lung Squamous Cell Carcinoma Trial in Shanghai (Afatinib)
Unknown status
- Lung Squamous Cell Carcinoma
- Afatinib
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Oct 25, 2019